Sygnature Discovery

JANUARY 17, 2023

Sygnature Discovery (“Sygnature”) is delighted to announce the acquisition of SB Drug Discovery, a world leading provider of ion channel and receptor drug discovery research delivering cell line generation and compound screening solutions in neuroscience and other therapeutic indications. SB is based in Glasgow and employs 55 people.

Compound Screening 52

Compound Screening Marketing Assay Development Drugs 52

Drug Discovery World

OCTOBER 4, 2022

Using its proprietary compound screening platform, Oligomerix discovers and develops differentiated, oral, small molecule inhibitors of tau self-association that are easy to administer and cost-effective. . million in 2022 to 12.7 Volume 23 – Issue 4, Fall 2022. million by 2050.” . About the author .

Disease 130

Disease Small Molecule Compound Screening Clinical Development 130

Drug Discovery World

JANUARY 26, 2023

The Market After over two years of the Covid-19 pandemic, 2022 year was somewhat of a return to normal for both the world at large and the pharmaceutical industry. As such, 2022 saw a marked fall in ROI for global pharmaceutical companies and their research and development activities. However, that is not to say it was an easy year.

Clinical Trials 246

Clinical Trials Drugs Trials Therapies 246

Drug Discovery World

JANUARY 23, 2023

They cannot be easily scaled or broadly applied to other therapeutic programs or disease areas, and the data generated from any compound screens will be narrowly focused on the target hypothesis. DDW Volume 24 – Issue 1, Winter 2022/2023 The post AI use in repurposing drugs for Covid-19 appeared first on Drug Discovery World (DDW).

Clinical Trials 147

Clinical Trials Compound Screening Drugs Trials 147

Broad Institute

JULY 26, 2022

Resources, services, and tools By Maria Nemchuk July 26, 2022 Breadcrumb Home Resources, services, and tools Key scientific datasets and computational tools developed by our scientists and their collaborators. Learn more PRISM Rapid, high-throughput multiplexed compound screening in genomically characterized human cancer cell-line models.

Compound Screening 52

Compound Screening FDA Approval Engineering RNA 52

Drug Discovery World

AUGUST 15, 2023

Manual patch-clamping of single cells has become a mainstay of functional electrophysiology, often used to follow up after novel hit compounds are identified by non-functional fluorescence or ligand binding methods, which are considerably higher in their throughput. 2022) Nature Reviews Drug Discovery, 21: 915–931. Scannell et al.

Drugs 130

Drugs Clinical Pharmacology Disease Engineering 130